Study shows Amgen’s Blincyto a better alternative than chemotherapy
Amgen’s new leukemia drug Blincyto increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. Results from its Phase 3 Tower study revealed that Blincyto almost doubled median overall survival versus chemotherapy among adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic Read More →
Read More →Genentech sues Amgen over biosimilar drug info
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
Read More →Amgen applies for FDA approval of Blincyto
Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014. “Acute Read More →
Read More →Our view: Amgen’s smart moves keep it poised to grow
From its perch in Thousand Oaks, Amgen continues to be one of the savvier companies in the biopharma space when it comes to navigating drug policy and drug pricing. It continues to win the battle to keep copycat biosimilars from eroding its core franchises while gaining approval for new drugs – the latest is for Read More →
Read More →
Drug sales for biotech giant Amgen boost bottom line
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease
The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →
Read More →Amgen funds STEM program for Girl Scouts
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
